Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CS7V | ISIN: US28623U1016 | Ticker-Symbol:
NASDAQ
20.05.24
21:57 Uhr
3,725 US-Dollar
+0,115
+3,19 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ELEVATION ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
ELEVATION ONCOLOGY INC 5-Tage-Chart

Aktuelle News zur ELEVATION ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.05.Elevation Oncology files for $350M mixed shelf1
02.05.Elevation Oncology GAAP EPS of -$0.231
02.05.Elevation Oncology, Inc. - 8-K, Current Report1
02.05.Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements79-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented...
► Artikel lesen
02.05.Elevation Oncology, Inc. - 10-Q, Quarterly Report1
08.04.Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 202483-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and...
► Artikel lesen
05.04.Elevation Oncology, Inc. - 8-K, Current Report2
07.03.Elevation Oncology Inc reports results for the quarter ended in December - Earnings Summary1
06.03.Elevation Oncology GAAP EPS of -$0.191
06.03.Elevation Oncology, Inc. Q4 Loss decreases, beats estimates2
06.03.Elevation Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
06.03.Elevation Oncology, Inc. - 8-K, Current Report1
06.03.Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements109--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 ---- Preclinical proof-of-concept...
► Artikel lesen
06.03.Elevation Oncology, Inc. - 10-K, Annual Report1
01.03.Elevation Oncology shares rise on new coverage by JPM, target upbeat4
22.02.Elevation Oncology begins Phase 1 trial in Japan for cancer therapy1
22.02.Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan228-- On track to provide update from ongoing Phase 1 clinical trial in mid-2024; additional data expected in 1H 2025 -- BOSTON, Feb. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV)...
► Artikel lesen
31.01.How Is The Market Feeling About Elevation Oncology?2
22.01.Elevation Oncology, Inc. - 8-K, Current Report3
12.01.YMAB, ELEV and CRGE among mid-day movers4
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1